Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;75(4):439-43.
doi: 10.1007/s40265-015-0368-z.

Vonoprazan: first global approval

Karly P Garnock-Jones  1
Affiliations
Review

Vonoprazan: first global approval

Karly P Garnock-Jones. Drugs. 2015 Mar.

Abstract

Vonoprazan (Takecab(®)) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication. Phase III development is underway for the prevention of recurrence of duodenal and gastric ulcer in patients receiving aspirin or NSAID therapy. Phase I development was conducted in the UK for gastro-oesophageal reflux; however, no further development has been reported. This article summarizes the milestones in the development of vonoprazan leading to this first approval for acid-related diseases.

PubMed Disclaimer

References

    1. J Med Chem. 2012 May 10;55(9):4446-56 - PubMed
    1. Curr Gastroenterol Rep. 2010 Dec;12(6):437-47 - PubMed
    1. PLoS One. 2014 May 20;9(5):e97688 - PubMed
    1. J Pharmacol Exp Ther. 2010 Oct;335(1):231-8 - PubMed
    1. J Pharmacol Exp Ther. 2011 Nov;339(2):412-20 - PubMed

MeSH terms

Substances

LinkOut - more resources